drugset / Trial / NCT01018186
Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the long-term safety of fluticasone furoate/GW642444
Timeline
- Start
- 2009-10-19
- Primary completion
- 2011-05-01
- Completion
- 2011-05-12
Publications
- Background Busse WW, O'Byrne PM, Bleecker ER, Lotvall J, Woodcock A, Andersen L, Hicks W, Crawford J, Jacques L, Apoux L, Bateman ED. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial. Thorax. 2013 Jun;68(6):513-20. doi: 10.1136/thoraxjnl-2012-202606. Epub 2013 Feb 25.
- Oba Y, Anwer S, Maduke T, Patel T, Dias S. Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2022 Dec 6;12(12):CD013799. doi: 10.1002/14651858.CD013799.pub2.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluticasone Furoate | Other / unclassified | — | Inhaled |
| Comparator | Fluticasone propionate | Other / unclassified | — | Inhaled |
| Subject | Vilanterol | Other / unclassified | — | Inhaled |